Maternal serum soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) were evaluated in preeclampsia to investigate whether these molecules could be helpful with regard to this pregnancy complication.
Preeclampsia complicates ϳ5% of all pregnancies and is one of the major causes of maternal and fetal morbidity and mortality in developed countries. The etiology of this complication has not yet been fully elucidated. An abnormal maternal immune response to antigenic challenge by the fetoplacental allograft 1,2 and a disturbance in vascular endothelial cell function 3 have been implicated in the pathogenesis of preeclampsia.
Indeed, vascular endothelial dysfunction appears to be common to the pathologic features of preeclampsia seen in the mother and to the local placental vascular damage, resulting in chronic hypoxia of the fetus, fetal growth restriction (FGR), and possibly intrauterine fetal death.
Vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) are transmembrane glycoproteins synthesized mainly by vascular endothelial cells. In the activated endothelium, these adhesion molecules, by binding firmly to integrin receptors on white blood cells, control the attachment and extravasation of circulating leukocytes through vessel walls in sites of injury, infection, and inflammation (the so-called "adhesion cascade"). 4 Hence, they are considered markers of the immune response and vascular endothelial activation.
The aim of this study was the comparative evaluation of the concentrations of the soluble forms of VCAM-1 (sVCAM-1) and ICAM-1 (sICAM-1) in the serum of preeclamptic women to determine whether the values of these adhesion molecules reflected the disease stage and could consequently be of help with regard to this pregnancy complication.
PATIENTS AND METHODS
This study was approved by the ethics committee of our teaching hospital; informed consent was obtained from all participants.
The study population was composed of the following groups of pregnant women, presented together with some clinical characteristics in Table 1 : A total of 30 pregnant women with preeclampsia and a mean gestational age of 35.5 weeks (13 of whom had FGR) who presented in one year to the Unit of High Risk Pregnancy of the Second Department of Obstetrics and Gynecology of the University of Athens at the Aretaieion University Hospital (subjects with a previous history of underlying hypertension, diabetes, or evidence of renal or collagen vascular disease were not included in the study). A total of 20 healthy pregnant women in the third trimester without any complication throughout pregnancy and with full-term healthy neonates (third trimester controls) matched in age and gestational age with the preeclamptic women were recruited from the pregnant women who were attended in our Department. A total of 15 of these 20 controls, evaluated in the second trimester, constituted group D (second trimester controls). A total of 7 of the 30 preeclamptic women, evaluated in the second trimester before the development of preeclampsia, constituted group E.
Preeclampsia was defined as blood pressure at Ն140/90 mm Hg on two or more consecutive occasions Ͼ4 hours apart and proteinuria at Ն0.3 gm in a 24-hour urine collection or corresponding to 1ϩ detected on reagent strip on two occasions Ͼ4 hours apart.
Pregnant women with preeclampsia as defined above and one of the following five characteristics were classified as presenting with severe preeclampsia: (1) Blood pressure at Ն160/110 mm Hg at two occasions 4 hours apart and proteinuria detected on a reagent strip 2ϩ or Ն0.5 gm/24 hours; (2) early onset of preeclampsia (Ͻ28 weeks' gestation); (3) fully developed eclampsia; (4) imminent eclampsia (i.e., persistent headache, blurred vision, or epigastric pain); (5) syndrome of hemolysis, elevated liver enzymes, and low platelets (aspartate aminotransferase at Ͼ72 U/l, lactate dehydrogenase at Ͻ600 U/l, bilirubin at Ͻ24 mmol/l, and a thrombocyte count of Ͻ100,000 ϫ 10 9 /l). FGR was defined as a birth weight that was less than or equal to the fifth percentile related to gestational age at birth according to Greek birthcards.
The subgroup with preeclampsia and FGR consisted of 8 women with mild preeclampsia and 5 women with severe preeclampsia, whereas the preeclamptic group without FGR consisted of 6 women with severe preeclampsia and 11 women with mild preeclampsia.
In preeclamptic patients, blood samples were taken at diagnosis. In the case of both second trimester controls and group E patients, aliquots of serum obtained for biochemical screening for chromosomal abnormalities in the second trimester were used for analysis. Serum was separated immediately after collection by centrifugation at 2500 revolutions per minute for 15 minutes at 4°C, aliquoted in polypropylene, pyrogen-free tubes, and stored at Ϫ30°C until analysis. The cell adhesion molecules sVCAM-1 and sICAM-1 were measured in the serum of pregnant women by enzyme-linked immunosorbent assay with the commercially available reagents Human Parameter sVCAM-1 (R&D Systems, Minneapolis, MN) and cell-free ICAM-1 (T Cell Diagnostics, Cambridge, Mass), respectively. The intra-and interassay coefficients of variation of the assays were 5.1% and 9.2%, respectively, for sVCAM-1 and 2.5% and 3.8%, respectively, for sICAM-1.
Results are given in mean values (Ϯ SD), and data were analyzed using parametric methods, as they showed a normal distribution (Kolmogorov-Smyrnov test). Multiple linear regression was used to examine the influence of the variables (gestational age at sampling and preeclampsia with or without FGR) on sVCAM-1 or sICAM-1 values. A one-way analysis of variance was used for comparisons of adhesion molecule values among preeclamptic groups and controls (third trimester), whereas group comparisons were performed using the Scheffe test. Student's t-test was used to compare sVCAM-1 or sICAM-1 values between second and third trimester controls or between second trimester controls and group E. A p value of Ͻ0.05 was considered significant.
RESULTS
The results of the linear regression model on sVCAM-1 and sICAM-1 are shown in Tables 2 and 3 . No significant influence of gestational age at sampling on maternal serum sVCAM-1 and sICAM-1 values was noticed in preeclamptic groups with and without FGR. When we considered the severity of preeclampsia, there was no significant difference in sVCAM-1 values between mild and severe preeclampsia (873 Ϯ 130 ng/ml and 898 Ϯ 117 ng/ml, respectively); however, the sVCAM-1 values in both of these groups were found to be significantly higher than in controls (668 Ϯ 186 ng/ml, p Ͻ 0.001). The maternal serum sVCAM-1 values in the study population are depicted in Figure 1 . Preeclamptic patients with FGR showed significantly higher sVCAM-1 values (981 Ϯ 148 ng/ml) compared with patients without FGR (846 Ϯ 84 ng/ml; p Ͻ 0.01); sVCAM-1 values in both preeclamptic groups with or without FGR were found to be significantly higher than those in the third trimester controls ( p Ͻ 0.0005 and p Ͻ 0.02, respectively). No significant difference was found in sVCAM-1 values (1) between the second (575 Ϯ 133 ng/ml) and third trimester controls and (2) in the second trimester between the controls and group E (normotensive pregnant women who developed preeclampsia later in the third trimester) (602 Ϯ 110 ng/ml).
The maternal serum sICAM-1 values in the study population are shown in Figure 2 . No significant difference was found in sICAM-1 concentrations (1) among each preeclamptic group (432 Ϯ 170 ng/ml with FGR; 342 Ϯ 122 without FGR) and the third trimester controls, (2) between second and third trimester controls (410 Ϯ 160 ng/ml and 361 Ϯ 99 ng/ml, respectively), and (3) between second trimester controls and group E.
The outcome of pregnancy both for the preeclamptic groups with and without FGR and for third trimester controls is given in Table 4 . Gestational age at birth was significantly lower than in controls only in the preeclamptic group with FGR ( p Ͻ 0.01). The birth weights of neonates in both preeclamptic groups were significantly lower than in controls; as expected, the lowest birth weights were observed for the preeclamptic group with FGR ( p Ͻ 0.01, p Ͻ 0.00001). Moreover, in the preeclamptic group with FGR, one intrauterine fetal death occurred and three neonates were transported to a neonatal intensive care unit. In the preeclamptic group without FGR, only 1 of the 17 neonates needed transportation to the neonatal intensive care unit.
DISCUSSION
The significant selective elevation of sVCAM-1 in the serum of preeclamptic women observed in this study confirms the results of some recent reports [5] [6] [7] [8] and is analogous to the previously reported increase of the vasoconstrictors endothelin-1 and von Willebrand factor in the blood of preeclamptic women 9 and to the decrease in the production of the vasodilator prostacyclin in endothelial cells. 10 Several pathways could be involved in the significant elevation of sVCAM-1 in preeclamptic women. Some authors have suggested that abnormal peroxidation of low-density lipoproteins takes place in preeclampsia, [11] [12] [13] because the development of atherosclerotic plaque is another process in which abnormal oxidation of low-density lipoproteins is enhanced.
14 Lesions similar to atherosclerotic plaque are found in placentas with preeclamptic pregnancies. However, serum from preeclamptic women induces VCAM-1 expression on human endothelial cells in vitro; 15 this effect is attributed to the observed increase of tree fatty acids in the serum of preeclamptic patients, 13, 15 because free fatty acids also produce a similar effect. 16 Furthermore, abnormally superficial placental implantation has also been observed in preeclampsia 17 that may also reflect abnormal VCAM-1 expression. Indeed, it has been reported that VCAM-1 plays an important role in the development of the placenta early in pregnancy and in the abnormal invasion of the trophoblast, 18 whereas in preeclampsia, undifferentiated cytotrophoblastic endothelial cells fail to acquire the vascular adhesion phenotype, thereby compromising the blood flow to the maternal-fetal interface. 19 Moreover, very recently sVCAM-1 has been also found to be a potent angiogenic factor. 20 Both VCAM-1 and ICAM-1 could also be synthesized by cells other than vascular endothelial cells. Nevertheless, the selective marked elevation of VCAM-1 in preeclampsia appears to support the view that damage and dysfunction of the vascular endothelium is implicated in the pathophysiology of preeclampsia. Furthermore, it seems that this adhesion molecule is not only involved in the etiologic mechanisms of the syndrome but may also be a major participant in the progression of this pregnancy complication.
The precise pathologic significance of adhesion molecules in the circulation remains unknown. Increased concentrations of sVCAM-1 in all preeclamptic groups may reflect enhanced expression of this molecule on the endothelial cell surface due to activation. Alternatively, they may also reflect increased shedding. The mechanisms by which cell adhesion molecules are released into the circulation remain unclear. It is probable that the adhesion molecules are cleaved or shed from the cell surface in a process designed to reduce the density of the molecules present on the membrane 21 and furthermore the adhesiveness of the cell for the cells carrying the relevant ligand.
Our findings with regard to comparable results for sICAM-1 between normotensive uncomplicated and preeclamptic pregnant women are in agreement with several previous studies; 4, 5, 7, 8 however, they are in contrast to other studies, which reported significantly higher sICAM-1 in preeclamptic pregnancies compared with normotensive uneventful pregnancies. [22] [23] [24] Even significantly lower sICAM-1 values in preeclampsia have been reported. 25 These conflicting results might derive from the small number of patients studied or from the observed large variations of sICAM-1 concentrations, as in our study. Hence, a larger group size may be required to reveal possible changes in the levels of serum sICAM-1 in preeclampsia.
Alternatively, differential changes between sVCAM-1 and sICAM-1 may result from differences in the mechanisms of cleavage or shedding or may reflect selective activation of endothelial cells, which express both adhesion molecules. In preeclampsia, the difference in changes between sVCAM-1 and sICAM-1 (although both of them are Figure 1 . Box-plots of sVCAM-1 levels in the five groups of the study population. f, mean; u, Ϯ SD; ‫,ׅ‬ maximum; Ќ, minimum. Group E represents pregnant women in the second trimester who developed preeclampsia in the third trimester. Figure 2 . Box-plots of sICAM-1 levels in the five groups of the study population. f, mean; u, Ϯ SD; ‫,ׅ‬ maximum; Ќ, minimum. Group E represents pregnant women in the second trimester who developed preeclampsia in the third trimester. expressed by activated endothelial cells) could be attributed to differentiated pathways of induction of the above two adhesion molecules on the endothelial cells. Thus, IL-4 induces VCAM-1-mediated attachment of T lymphocytes on the endothelium, although without upregulation of ICAM-1-mediated attachment on the endothelium. 26 It is also possible that VCAM-1 is more readily cleaved from the endothelial surface and thus appears in the circulation more easily than ICAM-1. 27 In all subgroups of established preeclampsia in the current study (mild and severe, or with and without FGR), sVCAM-1 was found to be significantly increased at the time of preeclampsia diagnosis compared with normotensive uncomplicated pregnancies. In contrast, measurement of sVCAM-1 in the second trimester of pregnancy does not seem helpful in detecting pregnancies that will develop preeclampsia later in the third trimester. These findings seem to indicate that elevated sVCAM-1 may be a consequence of the development of preeclampsia rather than an initiating factor. However, the following should be taken into consideration: The sample size in the second trimester (n ϭ 7) was small; therefore, a larger sample size may be needed to reach a statistically significant difference. Conversely, a paracrine action of membrane-bound VCAM-1 in the peripheral circulation may contribute to endothelial cell activation or damage; consequently, measurement of sVCAM-1 may not reflect complete etiopathologic information. Results that are similar to ours (i.e., that the selective elevation of sVCAM-1 is not an early preclinical feature of preeclampsia) have been reported recently; 7 an earlier study determined a very high predictive value for the early identification (3 to 15 weeks before the onset of the clinical symptoms) of women at risk of developing preeclampsia later on. 24 However, our findings suggest that in pregnancies already affected by preeclampsia, a higher sVCAM-1 concentration reflects a greater danger of FGR.
On the contrary, sVCAM-1 was not related to the degree of severity of preeclampsia, because similar sVCAM-1 values were found in the groups with mild and severe preeclampsia. This finding seems to be in agreement with the fact that proteinuria and blood pressure elevation are usually only a minor component of preeclampsia and do not correlate well with perinatal mortality and morbidity or with the development of FGR, due to reduced placenta perfusion. 28 Thus, it seems likely that elevated sVCAM-1 values in preeclampsia cannot be attributed to disturbances of the pathophysiology or function of kidneys caused by the syndrome itself, but rather might be the result of increased sVCAM-1 release in the circulation.
In summary, we conclude that the findings of the present study confirm the selective marked elevation of maternal serum sVCAM-1 in preeclampsia, although without any predictive value before the manifestation of the syndrome, and suggest that measurement of sVCAM-1 could contribute to the identification of FGR in this pregnancy complication.
